Alcon, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Julien Ouaddour from Bank of America Securities reiterated a Sell rating on the stock and has a CHF55.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Julien Ouaddour has given his Sell rating due to a combination of factors tied to both execution risks and valuation. While management’s 2026 guidance calls for mid‑single‑digit sales growth and margin expansion, he believes investors are already assuming a further upgrade that may be difficult to achieve, especially if revenue needs to accelerate above 8% in the first half to justify higher expectations.
He also highlights mounting competitive and pricing pressures in intraocular lenses, particularly in the U.S. and China, as well as limited margin benefit from product mix and uncertain contact lens demand after price hikes. Against this backdrop, he views the current valuation as demanding relative to peers, with modest scope for earnings upgrades, and therefore trims his price objective to CHF 55 while reiterating an Underperform (Sell) stance.